TapImmune Inc. (TPIV)

9.98
NASDAQ : Consumer Services
Prev Close 10.83
Day Low/High 9.69 / 10.91
52 Wk Low/High 2.58 / 13.55
Avg Volume 510.80K
Exchange NASDAQ
Shares Outstanding 11.98M
Market Cap 129.80M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

TapImmune Announces Pricing Of $70 Million Private Placement

TapImmune Announces Pricing Of $70 Million Private Placement

Financing Led by New Enterprise Associates (NEA)

TapImmune Creates Scientific Advisory Board To Support Clinical Development Of Multi-Antigen Cell Therapy Platform

Welcomes Renowned Thought Leaders Dr. Malcolm Brenner, Dr. Helen Heslop, and Dr. Cliona Rooney

TapImmune To Host Investor Breakfast To Discuss Proposed Merger With Marker Therapeutics

Live Audio Webcast Scheduled for May 17th at 8:00 a.m. CT

TapImmune And Marker Therapeutics Announce Entry Into Merger Agreement, Creating A Transformational Immuno-Oncology Platform

Transaction Adds Multi-Antigen Targeted Cell Therapy Platform to TapImmune's Peptide Vaccine Portfolio

TapImmune To Provide Fourth Quarter And Full Year 2017 Business Update Conference Call And Webcast

TapImmune To Provide Fourth Quarter And Full Year 2017 Business Update Conference Call And Webcast

Company to Provide Corporate and Clinical Overview on Thursday, April 5, 2018, 4:30pm ET

TapImmune Announces Publication Of Clinical Trial Results For The TPIV200 Cancer Vaccine In Clinical Cancer Research

TapImmune Announces Publication Of Clinical Trial Results For The TPIV200 Cancer Vaccine In Clinical Cancer Research

Phase 1 Demonstration of Safety and Long-Lasting Immune Responses in Ovarian and Breast Cancer

TapImmune Provides Update On PolyStart™ Vaccine Platform Applicable To Cancer And Infectious Disease

TapImmune Provides Update On PolyStart™ Vaccine Platform Applicable To Cancer And Infectious Disease

TapImmune, Inc. (OTCBB:TPIV), provides an update on the status of its PolyStart TM vaccine technology platform in light of recent global concerns regarding pandemic infections and emerging viral threats such as Ebola...

TapImmune CEO Provides Update On Corporate Activity And Progression Of Clinical Programs

TapImmune CEO Provides Update On Corporate Activity And Progression Of Clinical Programs

TapImmune is a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and infectious disease.

TapImmune Releases Positive Interim Data On Phase I Clinical Trial Of Folate Receptor Alpha Antigens In Ovarian And Breast Cancer

TapImmune Releases Positive Interim Data On Phase I Clinical Trial Of Folate Receptor Alpha Antigens In Ovarian And Breast Cancer

TapImmune Inc. (OTCQB:TPIV) is extremely pleased to report that analysis of the interim data from the first 13 patients in a Phase I clinical trial show that each of the patients treated have raised specific T-cell ...

TapImmune, Inc. Announces $2 Million Registered Direct Offering

TapImmune, Inc. Announces $2 Million Registered Direct Offering

TapImmune, Inc. (the “Company”), (OTCQB:TPIV), today announced that it has entered into a definitive agreement with an institutional investor for a registered direct placement of $2,000,000 of common stock at a ...

TapImmune's New Clinical Trial In Advanced Stage Ovarian Cancer Expands The Use Of Folate Receptor Alpha Peptide Antigens

TapImmune's New Clinical Trial In Advanced Stage Ovarian Cancer Expands The Use Of Folate Receptor Alpha Peptide Antigens

TapImmune Inc. (OTCQB:TPIV) is pleased to announce that a new grant funded Phase I clinical study on the safety and Immunogenicity of folate receptor alpha peptide vaccine in patients with advanced stage epithelial...

TapImmune Appoints Leading Immunotherapy Researcher To Chair Scientific Advisory Board

TapImmune Appoints Leading Immunotherapy Researcher To Chair Scientific Advisory Board

TapImmune Inc. (OTCQB:TPIV) is pleased to announce that Dr.

TapImmune Inc. Is Pleased To Provide An Update On Corporate Events And Milestones For 2014

TapImmune Inc. Is Pleased To Provide An Update On Corporate Events And Milestones For 2014

TapImmune Inc. (OTCQB:TPIV), A clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease is pleased to update ...

TapImmune Closes $1.16 Million Funding

TapImmune Closes $1.16 Million Funding

Company Retires Notes and 11.2 Million Warrants

TapImmune Provides Corporate Update

Company Highlights Major Milestones and Developments